Market Place
Sourcing Support
Hoth Therapeutics Updates On Cancer Therapeutic HT-KIT Results
29 Oct 2024 //
PR NEWSWIRE
Hoth Therapeutics Awarded US Patent For Alzheimer`s Treatment
15 Oct 2024 //
PR NEWSWIRE
Hoth Therapeutics Announces Promising Preclinical Results For Alzheimer`s Drug
17 Sep 2024 //
PR NEWSWIRE
Hoth Therapeutics Shares Positive Data for EGFRI-Associated Skin Toxicities
05 Sep 2024 //
PR NEWSWIRE
Hoth Therapeutics Expands Clinical Sites for HT-001 Phase 2a Trial
05 Sep 2024 //
PR NEWSWIRE
Hoth And Aronnax Partner On HT-KIT Cancer Therapeutic
15 Aug 2024 //
PR NEWSWIRE
Hoth, Wise Systems AI Deal For Drug Discovery
10 Jun 2024 //
PR NEWSWIRE
Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024
01 May 2024 //
PR NEWSWIRE
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
27 Mar 2024 //
PR NEWSWIRE
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT
26 Feb 2024 //
PR NEWSWIRE
Hoth Therapeutics to Attend CEO and Investor Conference, February 26-27, 2024
13 Feb 2024 //
PR NEWSWIRE
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Trial
18 Jan 2024 //
PR NEWSWIRE
Hoth Announces Expansion of FDA Cleared First-In-Human Trial For HT-001
27 Dec 2023 //
PR NEWSWIRE
Hoth Announces it Has Completed Manufacturing of Cancer fighting HT-KIT
05 Dec 2023 //
PR NEWSWIRE
Hoth Announces Completion of Pre-IND Meeting with FDA Regarding HT-KIT
14 Nov 2023 //
PR NEWSWIRE
Hoth to Present at NobleCon`s 19th Annual Emerging Growth Investor Conference
10 Nov 2023 //
PR NEWSWIRE
Hoth Announces Merveille.ai AI Initiative for Drug Discovery
05 Oct 2023 //
PR NEWSWIRE
FDA Grants Hoth Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients
02 Oct 2023 //
PR NEWSWIRE
Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering
15 Sep 2023 //
PR NEWSWIRE
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering
13 Sep 2023 //
PR NEWSWIRE
Hoth Announces FDA Accepts Pre-IND Submission for HT-KIT for Cancer Patients
11 Sep 2023 //
PR NEWSWIRE
Hoth Announces Positive Final Results from 14-day Phase 1b Trial of BioLexa
06 Sep 2023 //
PR NEWSWIRE
Hoth Therapeutics Announces Positive End Point Results of HT-ALZ Treatment
09 Aug 2023 //
PR NEWSWIRE
Hoth Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial
25 Jul 2023 //
PR NEWSWIRE
Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic
19 Jul 2023 //
PR NEWSWIRE
Hoth Announces IRB Approval for FDA Cleared First-In-Human Trial of HT-001
14 Jun 2023 //
PR NEWSWIRE
Hoth Announces Positive Results of HT-ALZ treatment for Alzheimer`s Disease
06 Jun 2023 //
PR NEWSWIRE
Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge
12 May 2023 //
PR NEWSWIRE
Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge
26 Apr 2023 //
PR NEWSWIRE
Hoth Announces Collaboration with First Active Site for its Phase 2 Trial
08 Mar 2023 //
PR NEWSWIRE
Hoth Announces Increased Positive Results of its Alzheimer`s Therapeutic HT-ALZ
08 Feb 2023 //
PR NEWSWIRE
Hoth Therapeutics Announces Closing of $10 M Private Placement
03 Jan 2023 //
PR NEWSWIRE
Hoth Therapeutics Announces $10 M Private Placement Priced At-the-Market
30 Dec 2022 //
PR NEWSWIRE
Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001
29 Dec 2022 //
PR NEWSWIRE
Hoth Announces Submission of Investigational New Drug Application for HT-001
01 Dec 2022 //
BIONJ
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements
09 Nov 2022 //
PRNEWSWIRE
Hoth reports positive data from Phase Ib atopic dermatitis trial
01 Nov 2022 //
CLINICALTRIALSARENA
Hoth`s Atopic Dermatitis Candidate Shows Improvement In Severity, Shares Jump
31 Oct 2022 //
FIANANCE YAHOO
Hoth Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening
24 Oct 2022 //
PRNEWSWIRE
Hoth Announces Partnership with Altasciences for Manufacturing HT-TBI
20 Sep 2022 //
PRNEWSWIRE
Hoth Therapeutics, HT-004, Shows Potential to Reduce Lung Inflammation
06 Sep 2022 //
PRNEWSWIRE
Hoth Tx`s HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer`s
12 Jul 2022 //
PRNEWSWIRE
Hoth Therapeutics Granted 180 Day Extension by Nasdaq with Bid Price Rule
29 Jun 2022 //
PRNEWSWIRE
Hoth Tx Announces HREC Approval in Australia for Next Phase of Trial of BioLexa
21 Jun 2022 //
PRNEWSWIRE
Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022
15 Jun 2022 //
PRNEWSWIRE
Hoth Tx to Extend Washington University Alzheimer`s Mouse Model Study
09 Jun 2022 //
PRNEWSWIRE
Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and TBI
19 Apr 2022 //
PRNEWSWIRE
Hoth Tx Announces Pricing of $7.0M Underwritten Public Offering
11 Apr 2022 //
PRNEWSWIRE
Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
11 Apr 2022 //
PRNEWSWIRE
Hoth Therapeutics` HT-KIT, Proves Effective Against Aggressive Cancer Cells
11 Apr 2022 //
PRNEWSWIRE
Hoth Tx Announces Pipeline Presentation at 2022 BIO International Convention
01 Apr 2022 //
PRNEWSWIRE
Hoth Tx Successfully Completes Mfg Feasibility of HT-KIT Drug Substance
22 Mar 2022 //
PRNEWSWIRE
Hoth Tx Selects NUVISAN for Mfg HT-001 Drug Batches for CLEER-001 Study
09 Feb 2022 //
PRNEWSWIRE
Hoth Tx Announces Presentation of the HT-ALZ Proof-of-Concept Preclinical Data
07 Feb 2022 //
PRNEWSWIRE
Hoth Tx Appoints John Cirrito and Carla Yuede to Scientific Advisory Board
31 Jan 2022 //
PRNEWSWIRE
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results
04 Jan 2022 //
PRNEWSWIRE
Hoth Therapeutics Announces Submission of Orphan Drug Designation
21 Dec 2021 //
BIOSPACE
Hoth Therapeutics, WuXi STA Sign API and Drug Product Contracts
09 Dec 2021 //
CONTRACTPHARMA
Hoth Nabs Sponsored Research Agreement to Develop Novel mRNA Cancer Therapeutic
16 Nov 2021 //
PRNEWSWIRE
Hoth Therapeutics, WuXi STA Ink API and Drug Product Pact
09 Nov 2021 //
CONTRACTPHARMA
